Antibiotic-resistant bacteria are spreading across European healthcare networks, with Italy reporting infection rates significantly higher than the European Union average.
New data from the European Centre for Disease Prevention and Control (ECDC) released on November 18 show that the continent is struggling to meet reduction targets set in 2023. While Europe aims to curb the misuse of antibiotics, blood infections from Klebsiella pneumoniae resistant to carbapenems have surged by 72% across the EU between 2019 and 2025.
According to ECDC estimates based on 2020 data, more than 35,000 people die annually in the EU and the European Economic Area as a direct consequence of infections caused by antimicrobial-resistant bacteria. The report, covering 30 countries, highlights a critical situation characterized by the spread of resistant bacteria and a progressive reduction in available therapeutic options.
Italy’s Resistance Levels
Italy remains one of the countries most affected by antimicrobial resistance. National data reveal that blood infections caused by Escherichia coli resistant to third-generation cephalosporins reached 24.61 cases per 100,000 inhabitants in 2025, more than double the EU average of 12.13.
While Italy has successfully met its national target for reducing Methicillin-resistant Staphylococcus aureus (MRSA), other indicators remain high. The incidence of Klebsiella pneumoniae resistant to carbapenems reached 10 cases per 100,000 inhabitants in 2025, a steady increase from 9.29 in 2023.
Historically, Italian cases rose from 6.99 per 100,000 in 2021 to 7.77 in 2022. Additionally, among Enterococcus faecium strains isolated from blood, vancomycin-resistant cases rose from 26.9% in 2021 to 37.2% in 2025, compared to an EU average of 17.2%. For Acinetobacter, carbapenem resistance now affects 77.1% of Italian strains, versus 31.5% in the EU.

Bacterial Transmission Trends
Bacteria do not require passports to cross borders; they travel through the movement of patients between hospitals and regions. A study published in Eurosurveillance on October 29, 2026, by Giulia Errico, Marius Linkevicius, Alessandra Lo Sciuto and colleagues, tracked the dissemination of the Klebsiella pneumoniae clone ST6668.
Researchers identified the strain in 19 NUTS-2 regions across Italy (8 regions) and five other EU countries (11 regions) between April 2022 and August 2026, confirming that high-risk lineages exploit the vulnerability of healthcare facilities, according to Geopop.
Comparison of Resistance Indicators
| Pathogen | Italy (2025) | EU Average (2025) |
|---|---|---|
| E. coli (cephalosporin-resistant) | 24.61 | 12.13 |
| K. pneumoniae (carbapenem-resistant) | 10.00 | 3.75 |
Figures represent cases per 100,000 inhabitants.

Hygiene and Antibiotic Use
Public health officials emphasize that simple interventions, such as hand hygiene, remain critical. Data from the Istituto Superiore di Sanità indicate that proper hand sanitation can prevent up to 50% of healthcare-associated infections. Despite this, the average consumption of hydroalcoholic solution in Italian ordinary wards was only 10.7 liters per 1,000 patient days in 2025, falling short of the 20-liter reference standard set by the World Health Organization.
Frequently Asked Questions
What makes Klebsiella pneumoniae particularly dangerous?
It is a bacterium that can colonize the human intestine without causing symptoms, but it can lead to severe conditions like pneumonia or sepsis in vulnerable patients. When it becomes resistant to carbapenems, it often resists many other available treatments, severely limiting medical options.
How does the ST6668 clone spread?
The clone is a highly mobile, multiresistant lineage that spreads primarily through the transfer of colonized patients between hospitals and across international borders. Researchers emphasize that screening patients at risk and communicating their carrier status during transfers are essential for containment.
The European Centre for Disease Prevention and Control was established in 2004, following the 2003 SARS outbreak, to strengthen Europe’s defenses against infectious diseases. It was set up in record time for an EU agency, with legislation passed by the spring of 2004 and operations beginning in May 2005.
Headquartered in Solna, Sweden, the organization covers a wide spectrum of activities, including surveillance, epidemic intelligence, and scientific advice. It also manages the scientific journal Eurosurveillance and maintains seven specific disease programs, one of which is dedicated exclusively to antimicrobial resistance and healthcare-associated infections.
What is the status of the 2030 EU targets?
Most countries, including Italy, are currently falling behind the reduction targets set by the EU Council. While the EU aims for 2.07 cases of carbapenem-resistant K. pneumoniae per 100,000 inhabitants by 2030, the current trend is moving in the opposite direction. It remains unknown when national surveillance systems will achieve the alignment necessary to fully curb these cross-border transmission chains.
Worth a look
- Boise Wastewater Shows High COVID, Flu, Enterovirus D68, Norovirus, Rotavirus
- Mariella Frostrup Swears By 15-Minute YouTube Kettlebell Workouts For Strength
- Black Heart Gold Pants Staff Unanimously Picks Iowa to Cover 8.5-Point Spread vs. Illinois (news-usa.today)
- Real Rates, Not Inflation Bets, Drove the 10-Year Yield to a 2002 High (daybreakwire.com)